CompletedPhase 2NCT00233454
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jason Robert Gotlib
- Principal Investigator
- Jason Robert Gotlib, M.D., M.SStanford University
- Intervention
- Midostaurin(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2011
Study locations (3)
- Stanford University School of Medicine, Stanford, California, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University-St. Louis, St Louis, Missouri, United States
Collaborators
Novartis · Novartis Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00233454 on ClinicalTrials.govOther trials for Acute mast cell leukemia
Additional recruiting or active studies for the same condition.